ARTICLE | Clinical News
OC000459: Completed Phase IIb enrollment
December 14, 2009 8:00 AM UTC
Oxagen completed enrollment of 440 patients in a double-blind, placebo-controlled, European Phase IIb trial evaluating oral OC000459 given once daily for 12 weeks. ...